Innate Pharma (IPHA) Stock Price, News & Analysis

Company Overview

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Key Stats

• Today's Range: $2.12 to $2.23
• 50-Day Range: $1.70 to $2.20
• 52-Week Range: $1.29 to $3.51
• Volume: 4,026 shs
• Average Volume: 13,573 shs
• Market Capitalization: $197.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 820th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Innate Pharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Innate Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Innate Pharma has a P/B Ratio of 19.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the outstanding shares of Innate Pharma have been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently decreased by 14.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.06% of the outstanding shares of Innate Pharma have been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Innate Pharma has recently decreased by 14.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.16% of the stock of Innate Pharma is held by institutions.

IPHA Stock Analysis - Frequently Asked Questions

How have IPHA shares performed this year?

Innate Pharma's stock was trading at $1.84 at the beginning of 2025. Since then, IPHA shares have increased by 16.3% and is now trading at $2.14.

When did Innate Pharma IPO?

Innate Pharma (IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Innate Pharma?

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

Company Calendar

• Today: 8/05/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPHA
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: 33-4-30-30-30-30
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Innate Pharma: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +414.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.52
• Current Ratio: 2.60
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $21.77 million
• Price / Sales: 9.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 19.45

Miscellaneous

• Outstanding Shares: 92,180,000
• Free Float: 62,787,000
• Market Cap: $197.27 million
• Optionable: Not Optionable
• Beta: 0.22